Media Coverage
SOCMA Member Ash Stevens Plans $20 Million Expansion
SOCMA Blog
(June 10, 2010)
SOCMA reviews Ash Stevens' expansion project that will increase product by 50 to 80 percent and allow them to hire 50 workers.
Only You Can Prevent Cross-Contamination
Contract Pharma
(May 1, 2010)
Gary A. Baker, Ph.D., Vice President of Quality Assurance and Regulatory Affairs, at Ash Stevens outlines effective cleaning procedures for CMOs.
Trends in Innovator Contract Pharmaceutical Manufacturing
Contract Pharma
(April 13, 2010)
The CMO business is being impacted by the rapidly changing global pharmaceutical market.
Cleaning & Validation
Manufacturing Chemist
(April 7, 2010)
Gary A. Baker, Ph.D., Vice President of Quality Assurance and Regulatory Affairs, Ash Stevens outlines how to build an effective cleaning program to avoid cross-contamination.
Fine Chemicals Producer Ash Stevens: Making Quality an Issue
Chemical Week
(March 22, 2010)
Alex Scott discusses Ash Stevens 50% revenue lift in 2010, expansion plans, and Silver Awards from SOCMA.
Clean and Validated
Cleanroom Technology
(March 22, 2010)
Contract manufacturer Ash Stevens outlines the solid cleaning procedures and analytical verification techniques used to prevent cross-contamination.
Podcast: Lucky and Good: Sourcing Success Is in the Details
Pharmaceutical Manufacturing
(March 10, 2010)
Michigan API manufacturer Ash Stevens’ emphasis on clear communication and product quality has (along with good fortune)
made it a home-grown success story with an international supplier and client base. Stephen Munk, President and CEO, shares
secrets of sourcing success.
Roundup of Informex 2010
Pharmaceutical Technology
(March 3, 2010)
Ash Stevens recent honor from SOCMA for achievement in environmental, health, safety, and security (EHS&S) performance is profiled.
Foreign Outsourcing of Development has Pitfalls
Pharmaceutical Formulation & Quality
(March 1, 2010)
James Hamby, Vice President, Business Development and Gary Baker, Vice President of Quality Assurance and Regulatory Affairs at Ash Stevens
Informex: Mixed Outlook but Optimism Prevails
Chemical Week
(February 26, 2010)
Alex Scott reviews Informex-attending companies, such as Ash Stevens, with growing revenues and factories.
Cover Story: Custom Chemicals
Chemical & Engineering News
(February 8, 2010)
Ash Stevens CEO Stephen Munk discusses multi-million dollar expansion plans and domestic outsourcing trends.
Quality by Design: Adding Another Dimension to Outsourcing
Pharmaceutical Technology
(January 2, 2010)
Gary A. Baker, vice-president of quality assurance and regulatory affairs for Ash Stevens, explains how Ash Stevens’ approach is aligned with quality by design principles.
Process Development And Scale-Up For APIs
sp2
(December 1, 2009)
sp2 profiles Ash Stevens $6 million dollar expansion and ChemStewards compliance.
Pharmaceutical Makers Look For Ingredients Closer To Home Purchasing
Purchasing
(November 19, 2009)
Stephen Munk explains reasons why it may be best to manufacture their critical ingredients closer to home, at least in the early stages of drug development.
CPhI Exhibitors Announce Expansions
Pharmaceutical Technology Sourcing and Management
(November 10, 2009)
Exhibitors announce capacity expansions, service enhancements and new products at CPhI Worldwide.
Fast track to market
Manufacturing Chemist
(October 1, 2009)
Case study: ASI helps bring anticancer drug to market early.
Anticancer Drugs: No option but to outsource?
Contract Pharma
(October 1, 2009)
Article discusses outsourcing trends in the anticancer market.
Pharma not concerned enough about environment when outsourcing; CEO
Outsourcing Pharma
(October 21, 2009)
CPhI coverage: Ash Stevens discusses the long-term benefits of sourcing to U.S.-based companies.
Construction starts on new Ash Stevens expansion project
Manufacturing Chemist
(October 20, 2009)
CPhI coverage: Dr. Stephen Munk comments on project to expand API manufacturing facility.
Ash Stevens starts $6m expansion
Outsourcing Pharma
(October 1, 2009)
James Hamby of Ash Stevens describes expansion plans that will bolster CMC capabilities.
Staying On Track with Fast Track
Pharma Magazine
(September/October, 2009)
Cutting average drug approval times from more than 18 months to less than a year, Fast Track can literally be a lifesaver for a patient with a life-threatening illness.
Stateside Surge In Pharma Chemicals
Chemical & Engineering News
(September 28, 2009)
Investment flows into the U.S. as drugmakers reassess their supply chains
Low Temperature Chemistry: Keep Your Cool
Speciality Chemicals
(July/August, 2009)
Industry leaders discuss low temperature chemistry technologies.
Michigan needs a united voice for biotech industry investment
The Detroit News
(May 22, 2009)
Industry leader Ash Stevens comments on Michigan biotech.
Best Practices for Cancer APIs
Pharmaceutical Manufacturing
(May 1, 2009)
Interview with Ash Stevens sheds light on API development processes and the new CMC alliance.
Business Roundup
Chemical & Engineering News
(April 13, 2009)
Ash Stevens joins Michigan CMC Alliance.
Largest Biotech Companies
Crain's Detroit Business
(April 6, 2009)
Ash Stevens ranked as 7th largest Detroit-area biotech company by Crain's.
An Unlikely Hot Spot
Chemical & Engineering News
(February 23, 2009)
Ash Stevens supports local pharmaceutical companies to revitalize the life sciences industry in Kalamazoo.
Fine Chemicals Firms Continue To Expand
Chemical & Engineering News
(February 16, 2009)
Post InformEx article in Chemical & Engineering News notes Ash Stevens as a company making expansions in 2009.
InformEx Report: Contract Manufacturers Expand
Pharmaceutical Technology Sourcing and Management
(February 4, 2009)
InformEx post show round up highlights Ash Stevens' investments in parallel synthesis and calorimetry instrumentation and certification in
SCOMA's ChemStewards program.
Ash Stevens Enhances Speed And Safety Of Scale-Up With New Investments In Parallel Synthesis And Calorimetry Instrumentation
InformEx Show Daily
(January 28, 2009)
Ash Stevens discusses new investments in parallel synthesis and calorimetry instrumentation.
Fine Chemical Producers Strive to Meet Demand for High-Potency APIs; A Potent Combination
ICIS Chemical Business
(January 19, 2009)
Dr. Stephen Munk, President and CEO of Ash Stevens, says ability "to deliver" is what differentiates high potency API manufacturers.
High-Potency API Expansion Plans Under Way as Market Soars
Chemical Week
(October 20, 2008)
Ash Stevens shares its high potency expansion plans at CPhI.
Sourcing and Management Launches Community of Experts Panel
Pharmaceutical Technology
(October 8, 2008)
Dr. Stephen Munk, President and CEO of Ash Stevens, is announced as a member of the Community of Experts Panel for Pharmaceutical Technology’s Sourcing and Management newsletter. The community of experts will provide reviews of technical articles and offer perspectives on topics of relevance.
The Key to Success in High-Potency APIs
sp2
(September 1, 2008)
Dr. Stephen Munk, President and CEO of Ash Stevens describes keys to success in the high-potency API manufacturing process. Munk also addresses challenges in the Fast Track approval process and outsourcing opportunities for European companies with US-based contractors.
On The Fast Track
Contract Pharma
(September 1, 2008)
Gary Baker, Vice President of Quality Assurance and Regulatory Affairs, and Vince Ammoscato, Director of Project Management, both of Ash Stevens, detail how clients and their contractors can ensure smooth passage of a drug through the Fast Track program.
Contained Chemistry
Chemical & Engineering News
(June 16, 2008)
This cover story explores how synthesizing highly potent compounds is a lucrative and growing niche for custom chemical manufacturers. As a notable developer of high potency anti-cancer compounds such as bortezomib, the API in Millennium Pharmaceuticals' multiple myeloma drug Velcade, Dr. Stephen Munk of Ash Stevens discusses containment strategies in general and the company’s approach.
Contract Research Services Support API Manufacture
sp2
(February 1, 2008)
President and CEO Dr. Stephen Munk describes Ash Steven’s evolution to a full-service contract manufacturer of APIs and its vision for the future in this in-depth feature.
Outsourcing Feature: CROs, CMOs Ride Outsourcing Growth
Drug Discovery News
(February 1, 2008)
In this feature article on the growth of CROs and CMOs, Ash Stevens’ president and CEO Dr. Stephen Munk discusses the advantages of being a U.S.-based contract manufacturer.
Custom Synthesis of APIs
Pharmaceutical Technology
(January 2, 2008)
In this story on various strategies for synthesing APIs and intermediates, Dr. Stephen Munk describes the chemical approach Ash Stevens and Ilex Oncology (now part of Genyzme) took in successfully developing Clofarabine, the API in Clolar, an anticancer therapy.
Ash Stevens Plots a Steady Growth Path
Pharmaceutical Technology
(November 7, 2007)
This feature article explores how Ash Stevens is able to grow at a healthy rate and secure contracts in a highly competitive marketplace.
New Capabilities for Ash Stevens
Specialty Chemical News
(November 1, 2007)
This feature article on developments at CPhI describes Ash Stevens’ new high containment capacity and low temperature pilot plant. Dr. Stephen Munk also explains the reasons behind the company’s success.
Fine Chemicals Upswing
Chemical & Engineering News
(October 8, 2007)
This CPhI recap reviewed investments being made by fine chemical companies, including an interview in which Dr. Stephen Munk shared news of Ash Stevens’ $2.5 million addition of high containment capacity.